Immunovia AB (IMMNOV) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, good morning, and welcome to the Q3 interim report for Immunovia. I'm excited to speak with you today about the milestones we've achieved and the progress that we've made in our mission to save lives through early detection of pancreatic cancer. This is a really important quarter for us as it marked the transition from being a development stage company to being a commercial stage company where we brought our Pancreasure test to the market and saw the initial response to that. We have been very excited about the responses that we've received throughout this presentation. I'll try to share a little bit of perspective from some of our customers about the pancreas share test. And here you can see one of those comments from Dr. Raj Kaswani, who works at Northwestern University, who is excited about offering this screening option to his patients. He calls out the fact that The test has a high sensitivity and a high specificity, and so it's a valuable option for their high-risk patients at Northwestern Medicine. On today's call, we'll talk about the launch of Pancreasure and share some initial results. We'll also talk about reimbursement milestones that we've achieved and what lies ahead. We'll briefly cover the Q3 financial results and our cash position. And then I'd like to share a little bit more information about the AFIRM clinical study that we announced results for a while back. Just as a reminder, before we talk about the results of the pancreas share launch, I thought it would be helpful to go back and make sure that we talked a little bit about the strategy that we're pursuing for the test. So one of the things we want to do is really build advocacy, build use among key opinion leaders who practice at the top high-risk surveillance centers across th...